Conduct Phase I and Clinical Pharmacokinetic studies on specific investigational new drugs sponsored by the Division of Cancer Treatment (DCT), National Cancer Institute (NCI). The Contractor shall provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and recommend a phase II dose.
| Ratain, M J; Staubus, A E; Schilsky, R L et al. (1988) Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48:4127-30 |
